149 related articles for article (PubMed ID: 25076334)
21. U.S. Food and Drug Administration approves paclitaxel protein-bound particles (Abraxane®) in combination with gemcitabine as first-line treatment of patients with metastatic pancreatic cancer.
Saif MW
JOP; 2013 Nov; 14(6):686-8. PubMed ID: 24216565
[No Abstract] [Full Text] [Related]
22. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.
Kozuch P; Grossbard ML; Barzdins A; Araneo M; Robin A; Frager D; Homel P; Marino J; DeGregorio P; Bruckner HW
Oncologist; 2001; 6(6):488-95. PubMed ID: 11743211
[TBL] [Abstract][Full Text] [Related]
23. [How I treat ... An advanced pancreatic cancer].
Polus M; Jerusalem G; Sautois B; Silvestre RM; Fillet G
Rev Med Liege; 2002 Mar; 57(3):131-4. PubMed ID: 12014258
[TBL] [Abstract][Full Text] [Related]
24. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.
Philip PA; Lacy J; Portales F; Sobrero A; Pazo-Cid R; Manzano Mozo JL; Kim EJ; Dowden S; Zakari A; Borg C; Terrebonne E; Rivera F; Sastre J; Bathini V; López-Trabada D; Asselah J; Saif MW; Shiansong Li J; Ong TJ; Nydam T; Hammel P
Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):285-294. PubMed ID: 31953079
[TBL] [Abstract][Full Text] [Related]
25. Is there a standard of care for the management of advanced pancreatic cancer?. Highlights from the Gastrointestinal Cancers Symposium. Orlando, FL, USA. January 25-27, 2008.
Saif MW
JOP; 2008 Mar; 9(2):91-8. PubMed ID: 18326919
[TBL] [Abstract][Full Text] [Related]
26. Gemcitabine and platinum combinations in pancreatic cancer.
Philip PA
Cancer; 2002 Aug; 95(4 Suppl):908-11. PubMed ID: 12209670
[TBL] [Abstract][Full Text] [Related]
27. Improved survival with combined gemcitabine and S-1 for locally advanced pancreatic cancer: pooled analysis of three randomized studies.
Yanagimoto H; Ishii H; Nakai Y; Ozaka M; Ikari T; Koike K; Ueno H; Ioka T; Satoi S; Sho M; Okusaka T; Tanaka M; Shimokawa T; Kwon AH; Isayama H
J Hepatobiliary Pancreat Sci; 2014 Oct; 21(10):761-6. PubMed ID: 24925464
[TBL] [Abstract][Full Text] [Related]
28. Pancreatic cancer: highlights from the 42nd annual meeting of the American Society of Clinical Oncology, 2006.
Saif MW
JOP; 2006 Jul; 7(4):337-48. PubMed ID: 16832131
[TBL] [Abstract][Full Text] [Related]
29. A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers.
Davis EJ; Griffith KA; Kim EJ; Ruch JM; McDonnell KJ; Zalupski MM
Am J Clin Oncol; 2018 Feb; 41(2):128-132. PubMed ID: 26535993
[TBL] [Abstract][Full Text] [Related]
30. Metastatic pancreatic adenocarcinoma: current standards, future directions.
Duffy A; Kummar S
Am J Ther; 2010; 17(1):79-85. PubMed ID: 19636248
[TBL] [Abstract][Full Text] [Related]
31. Gemcitabine mono-therapy versus gemcitabine plus targeted therapy in advanced pancreatic cancer: a meta-analysis of randomized phase III trials.
Ottaiano A; Capozzi M; De Divitiis C; De Stefano A; Botti G; Avallone A; Tafuto S
Acta Oncol; 2017 Mar; 56(3):377-383. PubMed ID: 28256961
[TBL] [Abstract][Full Text] [Related]
32. Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy.
Rivera F; López-Tarruella S; Vega-Villegas ME; Salcedo M
Cancer Treat Rev; 2009 Jun; 35(4):335-9. PubMed ID: 19131170
[TBL] [Abstract][Full Text] [Related]
33. Synergistic activity of troxacitabine (Troxatyl) and gemcitabine in pancreatic cancer.
Damaraju VL; Bouffard DY; Wong CK; Clarke ML; Mackey JR; Leblond L; Cass CE; Grey M; Gourdeau H
BMC Cancer; 2007 Jul; 7():121. PubMed ID: 17608948
[TBL] [Abstract][Full Text] [Related]
34. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer.
Sultana A; Smith CT; Cunningham D; Starling N; Neoptolemos JP; Ghaneh P
J Clin Oncol; 2007 Jun; 25(18):2607-15. PubMed ID: 17577041
[TBL] [Abstract][Full Text] [Related]
35. PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) for patients with advanced pancreatic cancer: the ghost regimen.
Reni M; Cereda S; Galli L
Cancer Lett; 2007 Oct; 256(1):25-8. PubMed ID: 17561341
[TBL] [Abstract][Full Text] [Related]
36. Pancreatic cancer: an update.
Kindler HL
Curr Oncol Rep; 2007 May; 9(3):170-6. PubMed ID: 17430687
[TBL] [Abstract][Full Text] [Related]
37. Pooled survival and response data from phase III randomized controlled trials for gemcitabine-based regimes in the treatment of advanced pancreatic cancer.
Arshad A; Al-Leswas D; Al-Taan O; Stephenson J; Metcalfe M; Steward WP; Dennison AR
Am J Clin Oncol; 2013 Aug; 36(4):411-4. PubMed ID: 21436672
[TBL] [Abstract][Full Text] [Related]
38. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
39. The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer.
Boeck S; Heinemann V
Future Oncol; 2008 Feb; 4(1):41-50. PubMed ID: 18240999
[TBL] [Abstract][Full Text] [Related]
40. A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma.
Ryan DP; Kulke MH; Fuchs CS; Grossbard ML; Grossman SR; Morgan JA; Earle CC; Shivdasani R; Kim H; Mayer RJ; Clark JW
Cancer; 2002 Jan; 94(1):97-103. PubMed ID: 11815964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
